MIR429: A Non-Coding RNA Molecule as A Potential Drug Target and Biomarker

MIR429: A Non-Coding RNA Molecule as A Potential Drug Target and Biomarker

MIR429, also known as mir-429, is a non-coding RNA molecule that has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

MIR429 is a small non-coding RNA molecule that consists of 21 amino acid residues. It is expressed in a variety of tissues and cells throughout the body and has been shown to play a role in various biological processes, including cell growth, differentiation, and inflammation.

One of the most promising aspects of MIR429 is its potential as a drug target. MIR429 has been shown to interact with several protein molecules, including the transcription factor NF-kappa-B and the protein PDGF-BB. These interactions suggest that MIR429 may play a role in regulating cellular processes that are important for the development and progression of these diseases.

In addition to its potential as a drug target, MIR429 has also been shown to be a potential biomarker for several diseases. For example, MIR429 has been shown to be downregulated in various types of cancer, including breast, ovarian, and prostate cancer. This suggests that MIR429 may be a useful biomarker for these diseases and may help doctors to diagnose and monitor the effectiveness of treatments.

Another promising aspect of MIR429 is its potential to target the immune system. MIR429 has been shown to interact with the immune checkpoint receptor PD-1 and has been shown to regulate the activity of T cells, which are important for immune surveillance. This suggests that MIR429 may play a role in modulating the immune system and may be a useful target for immunotherapy.

In conclusion, MIR429 is a non-coding RNA molecule that has been shown to be a potential drug target and biomarker for various diseases. Further research is needed to fully understand the role of MIR429 in these processes and to develop effective treatments based on this information.

Protein Name: MicroRNA 429

More Common Targets

MIR4290 | MIR4291 | MIR4292 | MIR4293 | MIR4294 | MIR4295 | MIR4296 | MIR4297 | MIR4298 | MIR4299 | MIR4300 | MIR4300HG | MIR4301 | MIR4302 | MIR4303 | MIR4304 | MIR4305 | MIR4306 | MIR4307 | MIR4308 | MIR4309 | MIR431 | MIR4310 | MIR4311 | MIR4312 | MIR4313 | MIR4314 | MIR4315-1 | MIR4315-2 | MIR4316 | MIR4317 | MIR4318 | MIR4319 | MIR432 | MIR4320 | MIR4321 | MIR4322 | MIR4323 | MIR4324 | MIR4325 | MIR4326 | MIR4327 | MIR4328 | MIR4329 | MIR433 | MIR4330 | MIR4418 | MIR4420 | MIR4423 | MIR4425 | MIR4427 | MIR4428 | MIR4429 | MIR4430 | MIR4431 | MIR4432 | MIR4432HG | MIR4433A | MIR4433B | MIR4435-1 | MIR4435-2 | MIR4435-2HG | MIR4436A | MIR4436B1 | MIR4436B2 | MIR4437 | MIR4440 | MIR4441 | MIR4442 | MIR4443 | MIR4444-1 | MIR4444-2 | MIR4445 | MIR4446 | MIR4447 | MIR4448 | MIR4449 | MIR4450 | MIR4451 | MIR4453 | MIR4453HG | MIR4454 | MIR4455 | MIR4456 | MIR4457 | MIR4458 | MIR4458HG | MIR4463 | MIR4465 | MIR4466 | MIR4467 | MIR4468 | MIR4469 | MIR4470 | MIR4472-1 | MIR4472-2 | MIR4474 | MIR4475 | MIR4476 | MIR4478